Skip to main content

Table 1 Comparison of baseline patient’s characteristics based on whole-body bone SPECT/CT results

From: Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?

Characteristic Total
(N = 115)
Negative bone SPECT/CT
(N = 88)
Positive bone SPECT/CT
(N = 27)
P value
Age (years)
 Median ± (IQRs) 73.2 (56–89) 73.2 (67.2–80) 73.2 (66–81.3) 0.79
Initial PSA (ng/mL)
 Median ± (IQRs) 9.4 (7.1–18.4) 9.2 (7.2–17.3) 9.4 (6.5–33.5) 0.45
Initial PSA (ng/mL), class n (%)     0.18
 0–10 65 (56.5) 49 (55.7) 16 (59.2)  
 10.01–20 26 (22.6) 23 (26) 3 (11.1)  
 > 20 24 (20.9) 16 (18) 8 (29.6)  
Tumor (T) stage, n (%)     0.10
 T1 – T2a 34 (30.6) 30 (35.7) 4 (14.8)  
 T2b 16 (14.4) 12 (14.3) 4 (14.8)  
 T2c – T4 61 (55) 42 (50) 19 (70.4)  
Gleason score, n (%)     < 0.01
 ≤ 6 32 (27.8) 31 (35.2) 1 (3.7)  
 7 (3–4) 29 (25.2) 24 (27.3) 5 (18.5)  
 7 (4 + 3) 30 (26.1) 21 (23.9) 9 (33.3)  
 ≥ 8 24 (20.9) 12 (13.6) 12 (44.4)  
D’Amico classification, n (%)     0.09
 Low-risk 10 (8.7) 10 (11.4) 0 (0)  
 Intermediate-risk 29 (25.2) 24 (27.3) 5 (18.5)  
 High-risk 76 (66.1) 54 (61.3) 22 (81.5)  
Initial treatment, n (%)     0.98
 RP 13 (11.3) 10 (11.4) 3 (11.1)  
 RP + EBRT 34 (29.6) 27 (30.7) 7 (25.9)  
 With positive surgical margins 22 (19) 15 (17) 7 (26) 0.15
 EBRT 50 (43.5) 34 (42) 13 (48.2)  
 Other (Brachytherapy, HIFU) 18 (15.6) 14 (15.9) 4 (14.8)  
 Adjuvant ADT 60 (52.2) 42 (47.7) 18 (66.7) 0.09
PSA nadir (ng/mL), median ± (IQRs) 0.1 (0.0–0.7) 0.1 (0.0–0.7) 0.1 (0.0–0.4) 0.62
Trigger PSA (ng/mL), median ± (IQRs) 5 (2.4–9.9) 4.4 (2.1–6.9) 12.5 (4.4–18.6) < 0.001
Trigger PSA (ng/mL), class n (%)     < 0.001
 PSA ≤10 ng /mL, 87 (75.7) 74 (84.1) 13 (48.2)  
 PSA > 10 ng/mL 28 (24.4) 14 (15.9) 14 (51.9)  
PSAdt (months), median ± (IQRs) 6.1 (3.3–13.4) 7.6 (3.7–16.7) 3.8 (2.1–6) < 0.001
PSAdt (months), n (%)     < 0.01
 ≤ 6 months 56 (48.7) 35 (39.8) 21 (77.8)  
 > 6 months 59 (51.3) 53 (60.2) 6 (22.2)  
  1. Abbreviations: RP Radical prostatectomy, EBRT External beam radiotherapy, HIFU High intensity focal ultrasound, ADT Androgen deprivation therapy, IQRs Interquartile ranges, PSAdt PSA doubling time